

Fabrice Carrat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6545654/publications.pdf>

Version: 2024-02-01

320
papers

19,240
citations

13865

67
h-index

15266

126
g-index

344
all docs

344
docs citations

344
times ranked

20051
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Lancet, The</i> , 2009, 374, 1617-1625.	13.7	996
2	Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. <i>American Journal of Epidemiology</i> , 2008, 167, 775-785.	3.4	927
3	Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2839.	7.4	742
4	Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. <i>New England Journal of Medicine</i> , 2011, 365, 2067-2077.	27.0	683
5	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019, 393, 1453-1464.	13.7	449
6	Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 141, 1621-1628.e5.	1.3	431
7	Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1679.	7.4	424
8	Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 337-346.e10.	1.3	411
9	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) â€“ NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	3.7	407
10	The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. <i>Gastroenterology</i> , 2005, 128, 297-303.	1.3	367
11	A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. <i>Statistics in Medicine</i> , 2004, 23, 3469-3487.	1.6	322
12	Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2013, 145, 166-175.e8.	1.3	311
13	Liver biopsy: The best, not the gold standard. <i>Journal of Hepatology</i> , 2009, 50, 1-3.	3.7	289
14	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. <i>Hepatology</i> , 2012, 56, 198-208.	7.3	277
15	The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. <i>Hepatology</i> , 2000, 32, 1196-1199.	7.3	265
16	Risk factors of influenza transmission in households. <i>British Journal of General Practice</i> , 2004, 54, 684-9.	1.4	241
17	Towards an HBV cure: state-of-the-art and unresolved questionsâ€”report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	12.1	234
18	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	1.3	232

#	ARTICLE	IF	CITATIONS
19	Baseline Values and Changes in Liver Stiffness Measured by Transient Elastography Are Associated With Severity of Fibrosis and Outcomes of Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2014, 146, 970-979.e6.	1.3	232
20	Effect of Influenza Vaccination of Nursing Home Staff on Mortality of Residents: A Cluster-Randomized Trial. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1580-1586.	2.6	222
21	Long-term Outcomes of Pandemic 2009 Influenza A(H1N1)-Associated Severe ARDS. <i>Chest</i> , 2012, 142, 583-592.	0.8	199
22	Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. <i>JAMA Internal Medicine</i> , 2022, 182, 19.	5.1	183
23	Effects of current and former cigarette smoking on the clinical course of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1403-1411.	3.7	179
24	Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Blood</i> , 2012, 119, 5996-6004.	1.4	175
25	Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients. <i>Gastroenterology</i> , 2002, 122, 652-658.	1.3	168
26	Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. <i>Gut</i> , 2011, 60, 198-203.	12.1	160
27	Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1432.	7.4	157
28	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. <i>Gut</i> , 2010, 59, 1363-1368.	12.1	155
29	Epidemiologic Mapping using the "Kriging" Method: Application to an Influenza-like Epidemic in France. <i>American Journal of Epidemiology</i> , 1992, 135, 1293-1300.	3.4	152
30	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	1.4	149
31	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , 2017, 130, 1377-1380.	1.4	146
32	Evaluation of Clinical Case Definitions of Influenza: Detailed Investigation of Patients During the 1995-1996 Epidemic in France. <i>Clinical Infectious Diseases</i> , 1999, 28, 283-290.	5.8	143
33	Monitoring epidemiologic surveillance data using hidden Markov models. , 1999, 18, 3463-3478.		126
34	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014, 63, 1416-1423.	12.1	122
35	Influenza Epidemics in the United States, France, and Australia, 1972-1997. <i>Emerging Infectious Diseases</i> , 2004, 10, 32-39.	4.3	121
36	How to Measure the Diagnostic Accuracy of Noninvasive Liver Fibrosis Indices: The Area Under the ROC Curve Revisited. <i>Clinical Chemistry</i> , 2008, 54, 1372-1378.	3.2	119

#	ARTICLE	IF	CITATIONS
37	Influenza Burden of Illness. Archives of Internal Medicine, 2002, 162, 1842.	3.8	117
38	Mortality burden of the 1918-1919 influenza pandemic in Europe. Influenza and Other Respiratory Viruses, 2009, 3, 99-106.	3.4	113
39	Severe Accidental Hypothermia Treated in an ICU. Chest, 2001, 120, 1998-2003.	0.8	111
40	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Alimentary Pharmacology and Therapeutics, 2016, 43, 252-261.	3.7	111
41	Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. Lancet Regional Health - Europe, The, 2022, 13, 100278.	5.6	109
42	Prediction of the Spread of Influenza Epidemics by the Method of Analogues. American Journal of Epidemiology, 2003, 158, 996-1006.	3.4	107
43	Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. Aids, 2006, 20, 419-427.	2.2	107
44	Transmissibility and geographic spread of the 1889 influenza pandemic. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8778-8781.	7.1	105
45	Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut, 2018, 67, 1261-1268.	12.1	104
46	Radiologic course of primary sclerosing cholangitis: Assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology, 2014, 59, 242-250.	7.3	102
47	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. Journal of Hepatology, 2017, 66, 39-47.	3.7	100
48	Risk factors of influenza transmission in households. International Congress Series, 2004, 1263, 291-294.	0.2	97
49	Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infectious Diseases, 2010, 10, 162.	2.9	97
50	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2063-2071.	1.9	96
51	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. American Journal of Hematology, 2018, 93, E114-E117.	4.1	94
52	Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology, 2017, 65, 152-163.	7.3	93
53	Population Modeling of Influenza A/H1N1 Virus Kinetics and Symptom Dynamics. Journal of Virology, 2011, 85, 2764-2770.	3.4	90
54	Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Journal of Hepatology, 2011, 55, 756-761.	3.7	89

#	ARTICLE	IF	CITATIONS
55	A 'small-world-like' model for comparing interventions aimed at preventing and controlling influenza pandemics. BMC Medicine, 2006, 4, 26.	5.5	88
56	Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibroic study – ANRS HC02. Journal of Hepatology, 2008, 48, 765-773.	3.7	87
57	Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 1324-1329.	4.4	86
58	A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. Journal of Viral Hepatitis, 2006, 13, 775-782.	2.0	85
59	Early Virologic Failure in HIV-Coinfected Hepatitis C Patients Treated With the Peginterferon-Ribavirin Combination. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 123-125.	2.1	85
60	Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut, 1999, 45, 218-222.	12.1	84
61	Surgical Mask to Prevent Influenza Transmission in Households: A Cluster Randomized Trial. PLoS ONE, 2010, 5, e13998.	2.5	84
62	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lympho study. American Journal of Hematology, 2015, 90, 197-203.	4.1	84
63	Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 47-52.	2.1	82
64	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	4.4	80
65	Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. Journal of Hepatology, 2006, 44, 455-461.	3.7	79
66	Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 177-188.	8.1	79
67	Hepatic steatosis in HIV-HCV coinfecting patients: analysis of risk factors. Aids, 2006, 20, 525-531.	2.2	77
68	Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. International Journal of Epidemiology, 2021, 50, 1458-1472.	1.9	75
69	Mortality Burden of the 2009 A/H1N1 Influenza Pandemic in France: Comparison to Seasonal Influenza and the A/H3N2 Pandemic. PLoS ONE, 2012, 7, e45051.	2.5	72
70	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Lancet Regional Health - Europe, The, 2021, 8, 100171.	5.6	70
71	Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina Faso. American Journal of Tropical Medicine and Hygiene, 2010, 82, 454-458.	1.4	66
72	The negative impact of HBV-HCV coinfection on cirrhosis and its consequences. Alimentary Pharmacology and Therapeutics, 2017, 46, 1054-1060.	3.7	66

#	ARTICLE	IF	CITATIONS
73	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	3.9	66
74	Factors associated with poor outcomes among adults hospitalized for influenza in France: A three-year prospective multicenter study. <i>Journal of Clinical Virology</i> , 2016, 79, 68-73.	3.1	65
75	Broad respiratory virus detection in infants hospitalized for bronchiolitis by use of a multiplex RT-PCR DNA microarray system. <i>Journal of Medical Virology</i> , 2012, 84, 979-985.	5.0	64
76	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 730-734.	5.8	63
77	Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv162.	0.9	61
78	The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model. <i>Value in Health</i> , 2007, 10, 98-116.	0.3	60
79	Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study. <i>PLoS Computational Biology</i> , 2014, 10, e1003568.	3.2	60
80	Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. <i>Clinical Microbiology and Infection</i> , 2017, 23, 253-259.	6.0	60
81	Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 374-380.	0.9	59
82	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 712-720.	3.7	59
83	Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1498-1511.	4.7	59
84	Estimating influenza latency and infectious period durations using viral excretion data. <i>Epidemics</i> , 2012, 4, 132-138.	3.0	58
85	Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. <i>Journal of Hepatology</i> , 2013, 58, 473-478.	3.7	58
86	Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections. <i>PLoS ONE</i> , 2015, 10, e0130378.	2.5	58
87	Influenza mortality among the elderly in France, 1980-90: how many deaths may have been avoided through vaccination?. <i>Journal of Epidemiology and Community Health</i> , 1995, 49, 419-425.	3.7	57
88	Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study. <i>Lancet Regional Health - Europe</i> , The, 2021, 7, 100148.	5.6	57
89	Progression of Fibrosis in HIV and Hepatitis C Virus-Coinfected Patients Treated with Interferon plus Ribavirin-Based Therapy: Analysis of Risk Factors. <i>Clinical Infectious Diseases</i> , 2008, 46, 768-774.	5.8	55
90	Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 188-195.	3.7	55

#	ARTICLE	IF	CITATIONS
91	A Sero-epidemiological Study of Arboviral Fevers in Djibouti, Horn of Africa. PLoS Neglected Tropical Diseases, 2014, 8, e3299.	3.0	54
92	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. Journal of Hepatology, 2015, 62, 807-815.	3.7	54
93	Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based "CONSTANCES" cohort. European Journal of Epidemiology, 2021, 36, 219-222.	5.7	54
94	Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. Lancet Public Health, The, 2021, 6, e408-e415.	10.0	54
95	Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005) Tj ETQq1 1 0.784314 rgBT /Overlook	2.2	53
96	Incidence, Presentation, and Prognosis of Small Bowel Adenocarcinoma in Patients with Small Bowel Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 1.	1.9	53
97	Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2021, 75, 565-571.	3.7	53
98	Personalized surveillance for hepatocellular carcinoma in cirrhosis " using machine learning adapted to HCV status. Journal of Hepatology, 2020, 73, 1434-1445.	3.7	52
99	Effect of indinavir on HIV-related wasting. Aids, 1998, 12, 1777-1784.	2.2	51
100	Online detection and quantification of epidemics. BMC Medical Informatics and Decision Making, 2007, 7, 29.	3.0	50
101	Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement. PLoS ONE, 2017, 12, e0163586.	2.5	49
102	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology, 2020, 73, 559-565.	3.7	47
103	Rapid and early virological response to chronic hepatitis C treatment with IFN α 2b or PEG-IFN α 2b plus ribavirin in HIV/HCV co-infected patients. Gut, 2007, 56, 1111-1116.	12.1	46
104	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. Journal of Hepatology, 2010, 53, 1006-1012.	3.7	46
105	Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. Gut, 2020, 69, 852-858.	12.1	46
106	Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 1283-1291.	9.1	45
107	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1213-1224.	6.1	44
108	When lockdown policies amplify social inequalities in COVID-19 infections: evidence from a cross-sectional population-based survey in France. BMC Public Health, 2021, 21, 705.	2.9	44

#	ARTICLE	IF	CITATIONS
109	Explaining rapid reinfections in multiple-wave influenza outbreaks: Tristan da Cunha 1971 epidemic as a case study. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2011, 278, 3635-3643.	2.6	43
110	Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1096-1107.	1.3	43
111	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. <i>Hepatology</i> , 2022, 76, 139-154.	7.3	42
112	Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment. <i>Clinical Infectious Diseases</i> , 2005, 41, 1806-1809.	5.8	41
113	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. <i>PLoS ONE</i> , 2011, 6, e26783.	2.5	41
114	Detection of Lung Cancer on Radiographs: Receiver Operating Characteristic Analyses of Radiologists'™, Pulmonologists'™, and Anesthesiologists'™ Performance. <i>Radiology</i> , 2004, 233, 799-805.	7.3	40
115	Applications of Extreme Value Theory in Public Health. <i>PLoS ONE</i> , 2016, 11, e0159312.	2.5	40
116	Chronic hepatitis C virus infection: Does it really impact health-related quality of life? A study in rural Egypt. <i>Hepatology</i> , 2004, 40, 1434-1441.	7.3	38
117	Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. <i>Journal of Hepatology</i> , 2010, 53, 238-244.	3.7	38
118	Ischemic stroke in giant-cell arteritis: French retrospective study. <i>Journal of Autoimmunity</i> , 2019, 99, 48-51.	6.5	38
119	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1138-1146.	3.7	37
120	A Scale of Methodological Quality for Clinical Studies of Radiologic Examinations. <i>Radiology</i> , 2000, 217, 69-74.	7.3	36
121	Burden of infections among 44,869 elderly in nursing homes: a cross-sectional cluster nationwide survey. <i>Journal of Hospital Infection</i> , 2011, 79, 254-259.	2.9	36
122	Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV genotype 4 in Egypt. <i>Journal of Viral Hepatitis</i> , 2015, 22, 245-253.	2.0	35
123	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 533-541.	3.7	35
124	Assessment and determinants of aesthetic discomfort in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 45-49.	0.9	34
125	Intense Co-Circulation of Non-Influenza Respiratory Viruses during the First Wave of Pandemic Influenza pH1N1/2009: A Cohort Study in Reunion Island. <i>PLoS ONE</i> , 2012, 7, e44755.	2.5	34
126	Detection of independent associations in a large epidemiologic dataset: a comparison of random forests, boosted regression trees, conventional and penalized logistic regression for identifying independent factors associated with H1N1pdm influenza infections. <i>BMC Medical Research Methodology</i> , 2014, 14, 99.	3.1	34

#	ARTICLE	IF	CITATIONS
127	Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. BMC Infectious Diseases, 2021, 21, 169.	2.9	33
128	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	3.7	33
129	Risk of hepatitis C virus transmission to surgeons and nurses from infected patients: model-based estimates in France. Journal of Hepatology, 1999, 30, 765-769.	3.7	32
130	Multiplex PCR performed of bronchoalveolar lavage fluid increases pathogen identification rate in critically ill patients with pneumonia: a pilot study. Annals of Intensive Care, 2014, 4, 35.	4.6	32
131	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. Autoimmunity Reviews, 2017, 16, 903-910.	5.8	32
132	Comparison of a New Method for the Direct and Simultaneous Assessment of LDL- and HDL-Cholesterol with Ultracentrifugation and Established Methods. Clinical Chemistry, 2000, 46, 493-505.	3.2	31
133	A virologic survey of patients admitted to a critical care unit for acute cardiorespiratory failure. Intensive Care Medicine, 2006, 32, 156-159.	8.2	31
134	Risk of Melanoma in Patients Who Receive Thiopurines for Inflammatory Bowel Disease Is Not Increased. American Journal of Gastroenterology, 2012, 107, 1443-1444.	0.4	31
135	Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1. JAMA Internal Medicine, 2016, 176, 603.	5.1	31
136	Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono- and co-infected compared with HIV- and HCV co-infected patients. Alimentary Pharmacology and Therapeutics, 2009, 30, 61-70.	3.7	30
137	Effect of Oseltamivir, Zanamivir or Oseltamivir + Zanamivir Combination Treatments on Transmission of Influenza in Households. Antiviral Therapy, 2012, 17, 1085-1090.	1.0	30
138	Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic?. Pediatric Nephrology, 2016, 31, 2299-2308.	1.7	29
139	Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. Journal of Infection, 2022, 85, e104-e108.	3.3	29
140	Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine, 2003, 21, 3614-3622.	3.8	28
141	Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. Infectious Diseases Now, 2021, 51, 380-382.	1.6	28
142	Repeated influenza vaccination of healthy children and adults: borrow now, pay later?. Epidemiology and Infection, 2006, 134, 63-70.	2.1	27
143	Influenza C virus high seroprevalence rates observed in 3 different population groups. Journal of Infection, 2014, 69, 182-189.	3.3	27
144	Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. Journal of Infectious Diseases, 2016, 213, 1735-1742.	4.0	27

#	ARTICLE	IF	CITATIONS
145	Characterization of pandemic influenza immune memory signature after vaccination or infection. <i>Journal of Clinical Investigation</i> , 2014, 124, 3129-3136.	8.2	26
146	Predicting Pneumonia and Influenza Mortality from Morbidity Data. <i>PLoS ONE</i> , 2007, 2, e464.	2.5	26
147	Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-Sant� cohort. <i>BMC Medicine</i> , 2021, 19, 290.	5.5	26
148	Detailed analysis of the genetic evolution of influenza virus during the course of an epidemic. <i>Epidemiology and Infection</i> , 2006, 134, 514-520.	2.1	25
149	Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV�hepatitis C virus-coinfected patients: HOMAVIC-ANRS HCO2 Study. <i>Antiviral Therapy</i> , 2009, 14, 839-845.	1.0	25
150	Field Effectiveness of Pandemic and 2009-2010 Seasonal Vaccines against 2009-2010 A(H1N1) Influenza: Estimations from Surveillance Data in France. <i>PLoS ONE</i> , 2011, 6, e19621.	2.5	25
151	Biased and unbiased estimation of the average length of stay in intensive care units in the Covid-19 pandemic. <i>Annals of Intensive Care</i> , 2020, 10, 135.	4.6	25
152	Trends in influenza vaccination behaviours �� results from the CoPanFlu cohort, France, 2006 to 2011. <i>Eurosurveillance</i> , 2013, 18, 20628.	7.0	25
153	Exploring cross-protection between influenza strains by an epidemiological model. <i>Virus Research</i> , 2004, 103, 101-105.	2.2	24
154	Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2007, 14, 639-644.	2.0	24
155	Simultaneous investigation of influenza and enteric viruses in the stools of adult patients consulting in general practice for acute diarrhea. <i>Virology Journal</i> , 2012, 9, 116.	3.4	24
156	Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. <i>RMD Open</i> , 2017, 3, e000344.	3.8	24
157	A Short-Term, Multicomponent Infection Control Program in Nursing Homes: A Cluster Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 569.e9-569.e17.	2.5	23
158	Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey. <i>Autoimmunity Reviews</i> , 2014, 13, 630-634.	5.8	23
159	Non-influenza respiratory viruses in adult patients admitted with influenza-like illness: a 3-year prospective multicenter study. <i>Infection</i> , 2020, 48, 489-495.	4.7	23
160	Factors of Weight Loss in Patients With HIV and Chronic Diarrhea. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 34-39.	0.3	22
161	Gastrointestinal Behcet��s-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1782-1788.	1.3	22
162	Pandemic Influenza Due to pH1N1/2009 Virus: Estimation of Infection Burden in Reunion Island through a Prospective Serosurvey, Austral Winter 2009. <i>PLoS ONE</i> , 2011, 6, e25738.	2.5	22

#	ARTICLE	IF	CITATIONS
163	Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. <i>Journal of Viral Hepatitis</i> , 2008, 15, 255-260.	2.0	21
164	Guidelines for infection control in nursing homes: a Delphi consensus web-based survey. <i>Journal of Hospital Infection</i> , 2011, 79, 75-89.	2.9	21
165	Nationwide surveillance of 18 respiratory viruses in patients with influenza-like illnesses: A pilot feasibility study in the French Sentinel Network. <i>Journal of Medical Virology</i> , 2011, 83, 1451-1457.	5.0	21
166	Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination. <i>Journal of Immunology</i> , 2013, 191, 623-631.	0.8	21
167	Factors Associated with Post-Seasonal Serological Titer and Risk Factors for Infection with the Pandemic A/H1N1 Virus in the French General Population. <i>PLoS ONE</i> , 2013, 8, e60127.	2.5	21
168	Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1399-1405.	1.3	21
169	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 879-884.	3.4	21
170	Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. <i>Journal of Hepatology</i> , 2021, 74, 37-47.	3.7	21
171	Effect of Antiviral Treatment on Serum Markers of Liver Fibrosis in HIV-Hepatitis C virus-Coinfected Patients: The Fibrovic 2 Study - ANRS HC02. <i>Antiviral Therapy</i> , 2009, 14, 211-219.	1.0	21
172	The influenza A (H1N1) pandemic in Reunion Island: knowledge, perceived risk and precautionary behaviour. <i>BMC Infectious Diseases</i> , 2013, 13, 34.	2.9	20
173	Statin and aspirin for prevention of hepatocellular carcinoma: What are the levels of evidence?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 9-11.	1.5	20
174	Inflammatory disorders associated with trisomy 8 myelodysplastic syndromes: French retrospective case-control study. <i>European Journal of Haematology</i> , 2019, 102, 63-69.	2.2	20
175	Air Pollution and Respiratory Drug Sales in the City of Le Havre, France, 1993-1996. <i>Environmental Research</i> , 1999, 81, 224-230.	7.5	19
176	Diagnosis Scoring for Clinical Identification of Children With Heterozygous Familial Hypercholesterolemia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, 456-463.	1.8	19
177	Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. <i>Clinical Microbiology and Infection</i> , 2011, 17, 732-737.	6.0	19
178	Randomised active programs on healthcareworkers' flu vaccination in geriatric health care settings in France: The VESTA study. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 126-132.	3.3	19
179	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. <i>PLoS ONE</i> , 2016, 11, e0157191.	2.5	19
180	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	2.5	19

#	ARTICLE	IF	CITATIONS
181	Quality of leucoreduced red blood cell concentrates: 5Âyears of follow-up in France. Vox Sanguinis, 2008, 94, 41-47.	1.5	18
182	Clinical validation of IFNÎ³/IL-10 and IFNÎ³/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Human Vaccines and Immunotherapeutics, 2014, 10, 104-113.	3.3	17
183	A systematic review on the effect of the organisation of hospital discharge on patient health outcomes. BMJ Open, 2016, 6, e012287.	1.9	17
184	High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?. Aids, 2007, 21, 1645-1648.	2.2	16
185	281 Thiopurine Therapy Is Associated with a Three-Fold Decrease in the Incidence of Advanced Colorectal Neoplasia in IBD Patients with Longstanding Extensive Colitis: Results from the CESAME Cohort. Gastroenterology, 2009, 136, A-54.	1.3	16
186	Therapeutic management and evolution of chronic hepatitis B: does <scp>HIV</scp> still have an impact? The <scp>EPiB</scp> 2012 study. Liver International, 2015, 35, 1950-1958.	3.9	16
187	Heterogeneous shedding of influenza by human subjects and its implications for epidemiology and control. Scientific Reports, 2016, 6, 38749.	3.3	16
188	Contribution of Genome-Wide Association Studies to Scientific Research: A Bibliometric Survey of the Citation Impacts of GWAS and Candidate Gene Studies Published during the Same Period and in the Same Journals. PLoS ONE, 2012, 7, e51408.	2.5	16
189	Age distribution of cases and deaths during the 1889 influenza pandemic. Vaccine, 2011, 29, B6-B10.	3.8	15
190	Integrative study of pandemic A/H1N1 influenza infections: design and methods of the CoPanFlu-France cohort. BMC Public Health, 2012, 12, 417.	2.9	15
191	Current State of and Needs for Hepatitis B Screening: Results of a Large Screening Study in a Low-Prevalent, Metropolitan Region. PLoS ONE, 2014, 9, e92266.	2.5	15
192	Seroprevalence of SARS-CoV-2 Among Adults in Three Regions of France Following the Lockdown and Associated Risk Factors: A Multicohort Study. SSRN Electronic Journal, 0, , .	0.4	15
193	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Reports, 2022, 4, 100390.	4.9	15
194	Children's mental and behavioral health, schooling, and socioeconomic characteristics during school closure in France due to COVID-19: the SAPRIS project. Scientific Reports, 2021, 11, 22373.	3.3	15
195	Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Journal of Infection, 2022, 84, e101-e104.	3.3	15
196	Antibiotic Treatment for Influenza does not Affect Resolution of Illness, Secondary Visits or Lost Workdays. European Journal of Epidemiology, 2003, 19, 703-705.	5.7	14
197	Impact of bucco-dental healthcare on the prevention of pneumonia in geriatrics: a cluster-randomised trial. Journal of Hospital Infection, 2011, 77, 78-80.	2.9	14
198	Representations of influenza and influenza-like illness in the community - a qualitative study. BMC Family Practice, 2013, 14, 15.	2.9	14

#	ARTICLE	IF	CITATIONS
199	Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIEG study. <i>Journal of Hepatology</i> , 2014, 61, 761-769.	3.7	14
200	A new out-patient care facility for HIV-infected destitute populations in Paris, France. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 1997, 9, 451-459.	1.2	13
201	Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. <i>Journal of Hepatology</i> , 2008, 49, 892-898.	3.7	13
202	Planning for the next influenza H1N1 season: a modelling study. <i>BMC Infectious Diseases</i> , 2010, 10, 301.	2.9	13
203	Assessment of healthcare worker influenza vaccination program in French geriatric wards: a cluster-randomized controlled trial. <i>Aging Clinical and Experimental Research</i> , 2010, 22, 450-455.	2.9	13
204	Risk factors of pandemic influenza A / H 1 N 1 in a prospective household cohort in the general population: results from the C o P an F lu - F rance cohort. <i>Influenza and Other Respiratory Viruses</i> , 2015, 9, 43-50.	3.4	13
205	The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1489-1492.	2.0	13
206	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , 2020, 19, 102446.	5.8	13
207	Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS Tj ETQq1 1 0.784314 rgBT /O	2.0	13
208	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015, 21, 5647.	3.3	13
209	Influenza and influenza-like illness in general practice: drawing lessons for surveillance from a pilot study in Paris, France. <i>British Journal of General Practice</i> , 1997, 47, 217-20.	1.4	13
210	2009 A(H1N1) Seroconversion Rates and Risk Factors among the General Population in Vientiane Capital, Laos. <i>PLoS ONE</i> , 2013, 8, e61909.	2.5	12
211	Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 261-276.	2.1	12
212	Immune activation, smoking, and vaccine response. <i>Aids</i> , 2017, 31, 171-173.	2.2	12
213	Persistent symptoms after the first wave of COVID-19 in relation to SARS-CoV-2 serology and experience of acute symptoms: A nested survey in a population-based cohort. <i>Lancet Regional Health - Europe</i> , The, 2022, 17, 100363.	5.6	12
214	Quality control of leucoreduced cellular blood components in France. <i>Vox Sanguinis</i> , 2002, 82, 67-71.	1.5	11
215	Causal analysis of H1N1pdm09 influenza infection risk in a household cohort. <i>Journal of Epidemiology and Community Health</i> , 2015, 69, 272-277.	3.7	11
216	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019, 70, e2-e3.	3.7	11

#	ARTICLE	IF	CITATIONS
217	Consequences of Misdiagnosis of Intrauterine Growth Retardation for Preterm Elective Cesarean Section. <i>Fetal Diagnosis and Therapy</i> , 1993, 8, 325-330.	1.4	10
218	Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working Adults. <i>Pharmacoeconomics</i> , 2003, 21, 215-224.	3.3	10
219	Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin. <i>Journal of Clinical Microbiology</i> , 2006, 44, 417-422.	3.9	10
220	“If you have the flu symptoms, your asymptomatic spouse may better answer the willingness-to-pay question”, <i>Journal of Health Economics</i> , 2009, 28, 873-884.	2.7	10
221	Gamma Glutamyl Transferase Elevation in HIV/Hepatitis C Virus-Coinfected Patients During Interferon-Ribavirin Combination Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 429-430.	2.1	10
222	Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008–2009 winter. <i>Clinical Microbiology and Infection</i> , 2013, 19, 196-203.	6.0	10
223	Intensification with pegylated interferon during treatment with tenofovir in HIV–hepatitis B virus coinfected patients. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1017-1026.	2.0	10
224	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101713.	1.5	10
225	Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France. <i>Infection</i> , 2022, 50, 257-262.	4.7	10
226	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	4.9	10
227	Multilabel classification of medical concepts for patient clinical profile identification. <i>Artificial Intelligence in Medicine</i> , 2022, 128, 102311.	6.5	10
228	Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. <i>Epidemiology and Infection</i> , 2005, 133, 305-314.	2.1	9
229	Field seasonal influenza vaccine effectiveness. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2453-2459.	3.3	9
230	Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 633-639.	1.6	9
231	Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. <i>BMC Medical Research Methodology</i> , 2017, 17, 160.	3.1	9
232	Estimating the burden of influenza-related and associated hospitalizations and deaths in France: An eight-season data study, 2010–2018. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 717-725.	3.4	9
233	Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5332-5341.	3.2	8
234	IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0121395.	2.5	8

#	ARTICLE	IF	CITATIONS
235	No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. PLoS ONE, 2016, 11, e0168640.	2.5	8
236	Comparing Patients'™ Opinions on the Hospital Discharge Process Collected With a Self-Reported Questionnaire Completed Via the Internet or Through a Telephone Survey: An Ancillary Study of the SENTIPAT Randomized Controlled Trial. Journal of Medical Internet Research, 2015, 17, e158.	4.3	8
237	Comparing Inpatient Satisfaction Collected via a Web-Based Questionnaire Self-Completion and Through a Telephone Interview: An Ancillary Study of the SENTIPAT Randomized Controlled Trial. Journal of Medical Internet Research, 2017, 19, e293.	4.3	8
238	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). Clinical Nutrition, 2022, 41, 610-619.	5.0	8
239	Comparing SF-36 Scores Collected Through Web-Based Questionnaire Self-completions and Telephone Interviews: An Ancillary Study of the SENTIPAT Multicenter Randomized Controlled Trial. Journal of Medical Internet Research, 2022, 24, e29009.	4.3	8
240	Risk Factors for Acute Liver Enzyme Abnormalities in HIV-Hepatitis B Virus-Coinfected Patients on Antiretroviral Therapy. Antiviral Therapy, 2007, 12, 1115-1126.	1.0	8
241	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. Scientific Reports, 2022, 12, .	3.3	8
242	Does nonadherence to local recommendations for empirical antibiotic therapy on admission to the intensive care unit have an impact on in-hospital mortality?. Therapeutics and Clinical Risk Management, 2009, 5, 491.	2.0	7
243	Hepatitis E Virus Infection in Sheltered Homeless Persons, France. Emerging Infectious Diseases, 2012, 18, 1031-1032.	4.3	7
244	Determinants of individuals'™ risks to 2009 pandemic influenza virus infection at household level amongst Djibouti city residents - A CoPanFlu cross-sectional study. Virology Journal, 2014, 11, 13.	3.4	7
245	Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patients. Aids, 2008, 22, 1234-1236.	2.2	6
246	Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. Aids, 2008, 22, 1385-1387.	2.2	6
247	Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections'™The Fluco French cohort. Journal of Clinical Virology, 2013, 58, 114-119.	3.1	6
248	Reply to 'A strong message is needed to address the issue of HCC recurrence after DAA therapy' Journal of Hepatology, 2016, 65, 1269-1270.	3.7	6
249	Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol. Pathogens, 2021, 10, 911.	2.8	6
250	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. JHEP Reports, 2021, 3, 100298.	4.9	6
251	Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons. World Journal of Gastroenterology, 2017, 23, 7037-7046.	3.3	6
252	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis and Cannabinoid Research, 2022, 7, 677-689.	2.9	6

#	ARTICLE	IF	CITATIONS
253	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infectious Diseases, 2022, 22, 94.	2.9	6
254	Emotional and attention-deficit/hyperactivity disorder symptoms of preterm vs. full-term children during COVID-19 pandemic restrictions. Pediatric Research, 2022, 92, 1749-1756.	2.3	6
255	Economic evaluations of neuraminidase inhibitors to control influenza. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 147-158.	1.4	5
256	Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis. HIV Medicine, 2009, 10, 417-421.	2.2	5
257	Risk perception and priority setting for intervention among hepatitis C virus and environmental risks: a cross-sectional survey in the Cairo community. BMC Public Health, 2010, 10, 773.	2.9	5
258	Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. Liver International, 2015, 35, 1833-1844.	3.9	5
259	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen- The ANRS CO20-CUPIC study. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 443-450.	1.5	5
260	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infectious Diseases, 2019, 19, 300.	2.9	5
261	Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. Journal of Viral Hepatitis, 2020, 27, 964-973.	2.0	5
262	Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 38-49.	3.9	5
263	Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: Clinical and economic impact. PLOS Currents, 2009, 1, RRN1121.	1.4	5
264	Acute and Chronic Sarcoid Arthropathies: Characteristics and Treatments From a Retrospective Nationwide French Study. Frontiers in Medicine, 2020, 7, 565420.	2.6	5
265	SARS CoV-2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine Based PrEP in 2020 - A Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero Cohorts. Open Forum Infectious Diseases, 0, , .	0.9	5
266	Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France. Viruses, 2022, 14, 957.	3.3	5
267	Liver fibrosis: Screening is not staging. Journal of Hepatology, 2009, 50, 1268-1269.	3.7	4
268	Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response. Journal of Viral Hepatitis, 2012, 19, 431-435.	2.0	4
269	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). Patient, 2017, 10, 605-614.	2.7	4
270	Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?. Clinical Infectious Diseases, 2018, 66, 317-318.	5.8	4

#	ARTICLE	IF	CITATIONS
271	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101459.	1.5	4
272	Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PLoS ONE, 2015, 10, e0145105.	2.5	4
273	Heterosubtypic Immunity to Influenza: Right Hypothesis, Wrong Comparison. Journal of Infectious Diseases, 2006, 193, 1613-1613.	4.0	3
274	Serum alpha-fetoprotein predicts virologic response to Hepatitis C treatment in HIV coinfectd patients. Aids, 2008, 22, 1513-1515.	2.2	3
275	Response to anti-HCV therapy in HIV+HCV-coinfectd patients: does the lipid profile really have an effect?. Antiviral Therapy, 2010, 15, 797-800.	1.0	3
276	WTW+an algorithm for identifying +who transmits to whom+in outbreaks of interhuman transmitted infectious agents. Journal of the American Medical Informatics Association: JAMIA, 2010, 17, 348-353.	4.4	3
277	Current management and recommendations on hepatitis B therapy in HIV-coinfectd patients. Hepatology International, 2013, 7, 437-442.	4.2	3
278	Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study. Vaccine, 2015, 33, 7015-7021.	3.8	3
279	Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1135-7.	2.3	3
280	Immunity against influenza A(H1N1) infections is determined by age at the time of initial strain circulation. Epidemiology and Infection, 2017, 145, 141-147.	2.1	3
281	Effect of resistance-associated substitutions on retreatment of direct acting antiviral-exposed patients in the real-world setting (ANRS CO22 HEPATHER). Journal of Hepatology, 2017, 66, S84.	3.7	3
282	Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection. Pharmacoepidemiology and Drug Safety, 2018, 27, 797-805.	1.9	3
283	Effectiveness of direct+acting antivirals for chronic hepatitis C treatment in migrant and non+migrant populations in France. Liver International, 2021, 41, 2328-2340.	3.9	3
284	Seasonal burden of severe influenza virus infection in the critically ill patients, using the Assistance Publique-H+pitaux de Paris clinical data warehouse: a pilot study. Annals of Intensive Care, 2021, 11, 117.	4.6	3
285	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 249-252.	3.9	3
286	Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	5.1	3
287	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Reports, 2022, 4, 100481.	4.9	3
288	A systematic analysis of all ICD10-coded death certificates in France, 2000, with a mention of influenza as cause of death. International Congress Series, 2004, 1263, 299-303.	0.2	2

#	ARTICLE	IF	CITATIONS
289	Viral pneumonia and respiratory sepsis: Association, causation, or it depends?*. Critical Care Medicine, 2007, 35, 639-640.	0.9	2
290	Public Health and Economic Impact of Vaccinating Children with a Quadrivalent live Attenuated Influenza Vaccine in France Using a Dynamic Transmission Model. Value in Health, 2014, 17, A674.	0.3	2
291	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules â€” A response. Journal of Hepatology, 2019, 71, 446.	3.7	2
292	Predictive models for hepatocellular carcinoma (HCC) occurrence in patients with chronic hepatitis C and sustained virological response (SVR) achieved with direct acting anti-viral (DAA) included in the ANRS CO22 hepather cohort. Journal of Hepatology, 2020, 73, S106.	3.7	2
293	Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study). Journal of Hepatology, 2020, 73, S797-S798.	3.7	2
294	Direct, indirect and total effect of HIV coinfection on the risk of nonâ€”liverâ€”related cancer in hepatitis C virusâ€”infected patients treated by directâ€”acting antivirals: a mediation analysis. HIV Medicine, 2021, 22, 924-935.	2.2	2
295	Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. Journal of Clinical Virology, 2021, 144, 104987.	3.1	2
296	Auto-Immune Origin of B Cells from HCV-Associated Lymphoma. Blood, 2015, 126, 1464-1464.	1.4	2
297	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617.		2
298	Effect of Maternal and Fetal Characteristics on Diagnosis of Intrauterine Growth Retardation. Fetal Diagnosis and Therapy, 1990, 5, 114-123.	1.4	1
299	Quantifying the burden of influenza: a prospective household contact study in France. International Congress Series, 2001, 1219, 61-66.	0.2	1
300	How much are patients willing to pay for an earlier alleviation of influenza?. International Congress Series, 2001, 1219, 67-71.	0.2	1
301	Factors associated with intensity of symptoms in patients seeking medical advice for flu. International Congress Series, 2004, 1263, 308-311.	0.2	1
302	General practitionersâ€™ management of influenza with or without neuraminidase inhibitors. European Journal of General Practice, 2007, 13, 157-159.	2.0	1
303	Integrating the applicability rate into the performance evaluation of noninvasive staging of liver fibrosis: A step towards a change from the â€œaccuracyâ€”to the â€œclinicalâ€”paradigm. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 691-692.	1.5	1
304	Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response. Journal of Infection, 2014, 68, 462-466.	3.3	1
305	Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. Journal of Viral Hepatitis, 2019, 26, 1276-1283.	2.0	1
306	Comparing interferonâ€”free with interferonâ€”based regimens in HCV patients: Rogers phenomenon and Simpsonâ€”s paradox. Journal of Viral Hepatitis, 2020, 27, 329-332.	2.0	1

#	ARTICLE	IF	CITATIONS
307	Body weight, body composition and the risk of SARS-CoV-2 infection in a large population-based sample. Journal of Internal Medicine, 2021, 290, 1268-1271.	6.0	1
308	Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patientsâ€™ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1050-1050.	3.7	1
309	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. Journal of Cannabis Research, 2022, 4, .	3.2	1
310	Rapid flu test and neuraminidase inhibitors in healthy adults: a cost-benefit analysis. International Congress Series, 2001, 1219, 73-79.	0.2	0
311	Ã‰valuation de l'incidence de la cirrhose biliaire primitive en 2007 en France. Revue Francophone Des Laboratoires, 2008, 2008, 25-28.	0.0	0
312	Reply to: From the CUPIC study: Great times are not coming (?). Journal of Hepatology, 2014, 60, 235-236.	3.7	0
313	Reply to: â€œFrom the CUPIC study: Great times are not coming (?)â€• Journal of Hepatology, 2014, 60, 900-901.	3.7	0
314	Letter: more studies are needed to elucidate the impact of <scp>HBV</scp>/<scp>HCV</scp> coinfection on cirrhosis and its consequencesâ€™ Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 543-544.	3.7	0
315	SAT-490-No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort. Journal of Hepatology, 2019, 70, e849-e850.	3.7	0
316	Direct-acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic?. Liver International, 2019, 39, 446-447.	3.9	0
317	Obstetrical morbidity related to anti-SSA antibodies: Data from a French monocentric retrospective study. Joint Bone Spine, 2019, 86, 523-524.	1.6	0
318	Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER). Liver International, 2021, 41, 1694-1698.	3.9	0
319	Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. Blood, 2013, 122, 3005-3005.	1.4	0
320	Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavirâ€™ new clues from Europe. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 659-659.	3.7	0